J&J Unit Asserts Bladder Drug Patent Again

Law360, New York (August 22, 2006, 12:00 AM EDT) -- Still trying to fend off allegations of anti-competitive behavior over Ditropan XL, Johnson & Johnson subsidiary Alza Corporation has hit Mylan Laboratories Inc. with another patent infringement lawsuit involving the blockbuster bladder control drug.

With an appeal pending, Alza filed suit on Monday in the U.S. District Court for the Northern District of West Virginia accusing Mylan of infringing on its patented intellectual property by trying to produce a generic version of Ditropan.

“Mylan Laboratories is liable for the infringement of the ‘355 patent because Mylan...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.